Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 3/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | SRPK1 | Q96SB4 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1941125 | 0.86 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2HPGDKDR | |
| Hydrochloric Acid SCHEMBL1941612 | 0.85 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2HPGDKDR | |
| SCHEMBL4018536 | 0.83 | KDR (0.64) | NPC1RAB9ASMN1; SMN2HPGDKDR | |
| SCHEMBL1786885 | 0.82 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2KDRKDM4E | |
| SCHEMBL1496399 | 0.81 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2HPGDKDR | |
| SCHEMBL4018153 | 0.81 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2HPGDKDR | |
| SCHEMBL1786747 | 0.81 | KDR (0.66) | NPC1RAB9ASMN1; SMN2KDRKDM4E | |
| SCHEMBL1786652 | 0.81 | KDR (0.45) | NPC1RAB9ASMN1; SMN2HPGDKDR | |
| SCHEMBL1783816 | 0.80 | KDR (0.46) | NPC1RAB9ASMN1; SMN2HPGDKDR | |
| SCHEMBL1941025 | 0.80 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2HPGDKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1864977-B1 | NOVEL CYCLIC COMPOUND HAVING PYRIMIDINYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-8507485-B2 | Cyclic compound having pyrimidinylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20110124646-A1 | Novel cyclic compound having pyrimidinylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| US-7906511-B2 | Cyclic compound having pyrimidinylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090291951-A1 | Novel Cyclic Compound Having Pyrimidinylalkylthio Group | SATEN PHARMACEUTICAL CO., LTD. (JP) | 2009-11-26 | — | — | US | disclosed |
| EP-1864977-A1 | NOVEL CYCLIC COMPOUND HAVING PYRIMIDINYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291951-A1 | Novel Cyclic Compound Having Pyrimidinylalkylthio Group | AGTR1, AGTR2, ARRB1 | NPC1 1451/4885RAB9A 2641/4885SMN1; SMN2 4691/4885 |
| US-20110124646-A1 | Novel cyclic compound having pyrimidinylalkylthio group | FLT1, VEGFA, FLT4 | NPC1 1069/4885RAB9A 3160/4885SMN1; SMN2 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.